These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18269344)

  • 1. Targeting signaling pathways in ovarian cancer.
    Reibenwein J; Krainer M
    Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising molecular targets in ovarian cancer.
    Blagden S; Gabra H
    Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Andersson M; Kamby C
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
    Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ
    Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
    Fischer B; Marinov M; Arcaro A
    Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody therapy of ovarian cancer.
    Nicodemus CF; Berek JS
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Duncan TJ; Al-Attar A; Rolland P; Scott IV; Deen S; Liu DT; Spendlove I; Durrant LG
    Clin Cancer Res; 2008 May; 14(10):3030-5. PubMed ID: 18483368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TrkB as a therapeutic target for ovarian cancer.
    Siu MK; Wong OG; Cheung AN
    Expert Opin Ther Targets; 2009 Oct; 13(10):1169-78. PubMed ID: 19694498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted trials in ovarian cancer.
    Ledermann JA; Raja FA
    Gynecol Oncol; 2010 Oct; 119(1):151-6. PubMed ID: 20591473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for ovarian cancer.
    Lorusso D; Pietragalla A; Mainenti S; Di Legge A; Amadio G; Scambia G
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):635-52. PubMed ID: 20604741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
    Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
    IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
    Markman M
    Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hedgehog signaling in ovarian cancer.
    Bhattacharya R; Kwon J; Ali B; Wang E; Patra S; Shridhar V; Mukherjee P
    Clin Cancer Res; 2008 Dec; 14(23):7659-66. PubMed ID: 19047091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.